Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications (Q83261042)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 2009

Language	Label	Description	Also known as
English	Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications	scientific article published on 01 January 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

multiple sclerosis

1 reference

based on heuristic

inferred from title

author name string

Shien Guo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Duygu Bozkaya

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Alexandra Ward

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Judith A O'Brien

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Khajak Ishak

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Randy Bennett

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ahmad Al-Sabbagh

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Dennis M Meletiche

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

39-53

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19178123%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

https://scigraph.springernature.com/pub.10.2165/00019053-200927010-00005

0 references

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A model for a smallpox-vaccination policy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost and health related quality of life consequences of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of relapses on development of residual deficit in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost of managing an episode of relapse in multiple sclerosis in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of relapse rate in MS clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment optimization in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology and natural history of multiple sclerosis: new insights

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomic analyses using discrete event simulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The development of a simulation model of the treatment of coronary heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

1 reference

https://pubmed.ncbi.nlm.nih.gov/19178123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83261042&oldid=1755832952"